Actively Recruiting
A Study of D-2570 in Patients With Active Systemic Lupus Erythematosus (SLE)
Led by InventisBio Co., Ltd · Updated on 2026-04-24
120
Participants Needed
1
Research Sites
150 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial designed to evaluate the efficacy and safety of D-2570 in the treatment of active systemic lupus erythematosus.
CONDITIONS
Official Title
A Study of D-2570 in Patients With Active Systemic Lupus Erythematosus (SLE)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- The patient voluntarily participates in this study after full informed consent.
- The age is 18 years 64 age 64 70 years, regardless of gender.
- Diagnosed with Systemic Lupus Erythematosus (SLE) at least 64 24 weeks prior to screening.
- SLEDAI-2K total score 64 8.
- On stable treatment for systemic lupus erythematosus at least 4 weeks prior to randomization, and should remain at a stable dose throughout the trial period.
You will not qualify if you...
- History of infection as defined in the protocol.
- Any of the medical diseases or disorders listed in the protocol.
- Significant, uncontrolled or unstable disease in any organ.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Linfen Central Hospital
Linfen, Jiangxi, China
Actively Recruiting
Research Team
H
Hang Ren, Master
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here